Loading quotes...
Forecast
The analysts' average price target is €10.71 (+382.43%). The median is €10.71 (+382.43%).
| Buy |
6 |
| Hold |
0 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -18.99m | 49.58% |
| EBITDA | -18.92m | 50.07% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €130.82m |
Number of shares | 59.1m |
52-week high/low | €6.98 - €2.04 |
| Dividends | No |
Beta | 1.47 |
P/E ratio | -1.82 |
PEG ratio | -0.11 |
P/B ratio | 0.94 |
P/S ratio | 0.00 |
Company profile
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
| Name | PROTARA THERAPEUTICS INC |
| CEO | Jesse Shefferman |
| Headquarters | New York City,
ny USA |
| Website | |
| Sector | Consumer Staples |
| Industry | Food Products |
| IPO | 22/10/2014 |
| Employees | 46 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | TARA |
Frankfurt | 1KPA.F |
Düsseldorf | 1KPA.DU |
München | 1KPA.MU |
